Bone Therapeutics has appointed Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Director effective 26 May 2017.
The company said that Swinson and Marron will replace Jacques Reymann and Jean-Jacques Verdickt.
Commenting on his appointment, Steve Swinson said: “Bone Therapeutics leads the field in regenerative approaches to orthopaedics and bone diseases, and its allogeneic cell therapy platform has the potential to transform medicine in these areas. I`m delighted to have the opportunity to use my deep experience in orthopaedic medical technology to help support this Company as it advances its technology towards commercialization.”
Damian Marron added: “I am very excited to be joining Bone Therapeutics. I look forward to bringing my experience in strategic development and my expertise in cell therapy to support the company as it approaches key value inflection points with its innovative allogeneic cell therapy platform.”